Inhibiting CXCR4 in an experimental cancer medicine study by one week continuous infusion of the small-molecule inhibitor AMD3100 induced an integrated immune response that was detected by transcriptional analysis of paired biopsies of metastases from patients with microsatellite stable colorectal and pancreatic cancer.
[Proceedings of the National Academy of Sciences of the United States of America]
6445212 YRCFFA2W items 1 apa default asc 1
Biasci, D., Smoragiewicz, M., Connell, C. M., Wang, Z., Gao, Y., Thaventhiran, J. E. D., Basu, B., Magiera, L., Johnson, T. I., Bax, L., Gopinathan, A., Isherwood, C., Gallagher, F. A., Pawula, M., Hudecova, I., Gale, D., Rosenfeld, N., Barmpounakis, P., Popa, E. C., … Jodrell, D. I. (2020). CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2013644117 Cite